OTCMKTS:PHMMF

Pharma Mar (PHMMF) Stock Forecast, Price & News

$41.21

-3.67 (-8.17%)

(As of 05/8/2023)

Compare

Today's Range: $41.21
▼
$42.07
50-Day Range: $41.21
▼
$69.40
52-Week Range: $41.21
▼
$79.38

Volume: 300 shs
Average Volume: 190 shs
Market Capitalization: $742.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Pharma Mar (OTCMKTS:PHMMF) Stock

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

Receive PHMMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter.

PHMMF Stock News Headlines

April 22, 2023 | msn.com

NEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy Recommendation

March 29, 2023 | americanbankingnews.com

Pharma Mar (OTCMKTS:PHMMF) Hits New 12-Month Low at $47.70

May 29, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

March 27, 2023 | marketwatch.com

Pharmaceutical Excipients Market Top Players By 2031

March 25, 2023 | news.yahoo.com

Pharmaceutical company to open in McHenry

March 24, 2023 | markets.businessinsider.com

Innate Pharma (IPHA) Receives a Buy from H.C. Wainwright

March 16, 2023 | bizjournals.com

Big Pharma companies back new startup out of Mass General Brigham

November 9, 2022 | markets.businessinsider.com

Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2023

May 29, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

October 10, 2022 | yahoo.com

European Commission suspects pharma group Teva broke antitrust rules

August 30, 2022 | apnews.com

Pharmacists Database List of Emails, Phone Numbers, Contact Information

January 11, 2022 | finance.yahoo.com

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

November 11, 2021 | finanznachrichten.de

PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan

October 28, 2021 | news.yahoo.com

Spain's PharmaMar posts 58% drop in 9-mth profit despite higher revenues

October 28, 2021 | reuters.com

Spain's PharmaMar nine-month net profit falls 58%

July 29, 2021 | nasdaq.com

Spain's PharmaMar sales rise on demand for cancer treatments

May 26, 2021 | reuters.com

Spain's PharmaMar says COVID-19 treatment shows clinical efficacy in trials

April 30, 2021 | investing.com

Pharma Mar SAU (PHMR)

April 29, 2021 | reuters.com

Spain's regulator lets PharmaMar test treatment on COVID-19 patients

January 27, 2021 | cn.reuters.com

UPDATE 2-PharmaMar soars 21% after journal Science confirms drug's efficacy against COVID

January 26, 2021 | reuters.com

Science Magazine confirms efficacy of PharmaMar's Plitidepsin against COVID-19

January 26, 2021 | reuters.com

UPDATE 1-PharmaMar says paper in journal Science confirms vaccine efficacy

December 28, 2020 | markets.businessinsider.com

Pharma Mar SA Bearer Shs Stock , PHMMF

December 15, 2020 | nasdaq.com

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1%

September 11, 2020 | msn.com

Cambio en el Ibex: PharmaMar ocupará el puesto de Ence el 21 de septiembre

May 26, 2020 | finance.yahoo.com

Pharma Mar, S.A. (PHMMF)

April 28, 2020 | finance.yahoo.com

PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PHMMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter.

PHMMF Company Calendar

Today: 5/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Private households
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PHMMF
Previous Symbol: NASDAQ:PHMMF
CUSIP: N/A
CIK: N/A
Web: www.pharmamar.com
Phone: (491) 846-6000
Fax: 34-91-846-6001
Employees: 477
Year Founded: 1986

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $271.91 million
Price / Sales: 2.73
Cash Flow: $6.47 per share
Price / Cash Flow: 6.37
Book Value: $11.69 per share
Price / Book: 3.52

Miscellaneous

Outstanding Shares: 18,010,000
Free Float: 17,672,000
Market Cap: $742.10 million
Optionable: Not Optionable
Beta: 0.36

Social Links

Key Executives

José Maria Fernández de Sousa-Faro
Executive Chairman, President & CEO

Maria Luisa de Francia Caballero
Chief Financial Officer

Carmen Cuevas Marchante
Director-Research & Development

Luis Rupérez Cuenca
Director-Human Resources & Information Technology

Nadia Badri
Vice President-Medical Affairs

Key Competitors

View All Competitors

PHMMF Stock - Frequently Asked Questions

Should I buy or sell Pharma Mar stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharma Mar in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHMMF shares.
View PHMMF analyst ratings or view top-rated stocks.
How have PHMMF shares performed in 2023?: Pharma Mar's stock was trading at $69.3870 at the beginning of 2023. Since then, PHMMF shares have decreased by 40.6% and is now trading at $41.2050.
View the best growth stocks for 2023 here.
What is Pharma Mar's stock symbol?: Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."
How do I buy shares of Pharma Mar?: Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharma Mar's stock price today?: One share of PHMMF stock can currently be purchased for approximately $41.21.
How much money does Pharma Mar make?: Pharma Mar (OTCMKTS:PHMMF) has a market capitalization of $742.10 million and generates $271.91 million in revenue each year.
How many employees does Pharma Mar have?: The company employs 477 workers across the globe.
How can I contact Pharma Mar?: Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The official website for the company is www.pharmamar.com. The company can be reached via phone at (491) 846-6000, via email at investorrelations@pharmamar.com, or via fax at 34-91-846-6001.

This page (OTCMKTS:PHMMF) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial